Bioengineers at The University of Texas at Dallas have created a novel gene-delivery system that shuttles a gene into a cell, but only for a temporary stay, providing a potential new gene-therapy strategy for treating disease.
The approach offers distinct advantages over other types of gene therapies under investigation, said Richard Taplin Moore MS’11, a doctoral student in bioengineering in the Erik Jonsson School of Engineering and Computer Science. He is lead author of a study describing the new technique in the Jan. 30 issue of the journal Nucleic Acids Research.
“In other gene therapy approaches, the therapeutic genetic messages being delivered can persist for a long time in the patient, potentially lasting for the patient’s entire lifetime,” Moore said. “This irreversibility is one reason gene therapies are so difficult to get approved.”
The UT Dallas study describes proof-of-concept experiments in which a gene carrying instructions for making a particular protein is ordered to self-destruct once the cell has “read” the instructions and made a certain quantity of the protein. In its experiments with isolated human kidney cells, the research team successfully delivered — and then destroyed — a test gene that makes a red fluorescent protein.
More research is needed to determine whether and how well the system might work in living organisms. But Moore said the ultimate goal is to refine the method to deliver genes that produce therapeutic proteins or drugs. The nature of the gene delivery system offers more control over how much protein the gene produces in cells or tissues. Because it does not alter the cell permanently, the method also sidesteps potential health problems that can occur if a gene is delivered to the wrong place in a cell’s genome.
“Our goal was to create a delivery system for therapeutic genes that would self-destruct, giving us more control over the delivered DNA by limiting the time it resides in cells,” Moore said.
Read more: Team Creates New Approach to Gene Therapy
The Latest on: Gene Therapy
via Google News
The Latest on: Gene Therapy
- The Incredible Gene-Therapy Breakthroughs to Cure Blindnesson June 26, 2020 at 5:34 am
Some involved the gene-editing technique known as CRISPR. One involves putting a specially engineered gold particle into the retina.
- CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapyon June 25, 2020 at 1:25 pm
CSL Behring is joining the chase for a genetic treatment for hemophilia by acquiring a uniQure gene therapy that’s already in late-stage testing. King of ...
- CSL Behring pays $450M to strengthen gene therapy pipelineon June 25, 2020 at 8:57 am
King of Prussia's CSL Behring acquires gene therapy candidate in a deal that includes a $450M upfront payment.
- The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapyon June 25, 2020 at 8:32 am
The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) ...
- FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Productson June 25, 2020 at 7:20 am
A “new playbook” is needed to ensure consistent chemistry, manufacturing, and controls (CMC) reviews for gene therapy products, the lack of which is ...
- Gene therapy and CRISPR strategies for curing blindnesson June 25, 2020 at 6:31 am
In a piece originally published on The Conversation, Hemant Khanna, PhD, comments on recent studies that use CRISPR to treat diseases that cause blindness and explains why the eye is an ideal organ ...
- Gene therapy and CRISPR strategies for curing blindness (Yes, you read that right)on June 25, 2020 at 5:38 am
In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness. Researchers at U.S.- ...
- CSL to pay $450M to buy uniQure's hemophilia B gene therapyon June 25, 2020 at 3:20 am
CSL Behring has struck a deal to buy uniQure’s late-phase hemophilia B gene therapy AMT-061 for $450 million upfront. The agreement will catapult CSL to the front of the race to bring a hemophilia B ...
- Gene Therapy and Antisense Drugs Market Detailed Study Analysis and Forecast by 2025on June 24, 2020 at 10:53 pm
Since an escalating number of patients are being diagnosed with cancer every day, the global demand for gene therapy and antisense drugs is bound to ...
- uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapyon June 24, 2020 at 1:05 pm
CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion, ...
via Bing News